NO317547B1 - Fiskebukspyttkjertel-sykdomsvirus, fremgangsmate for diagnostisering av sykdom og for isolering av virus, samt vaksine og diagnostisk reagens. - Google Patents
Fiskebukspyttkjertel-sykdomsvirus, fremgangsmate for diagnostisering av sykdom og for isolering av virus, samt vaksine og diagnostisk reagens. Download PDFInfo
- Publication number
- NO317547B1 NO317547B1 NO19954135A NO954135A NO317547B1 NO 317547 B1 NO317547 B1 NO 317547B1 NO 19954135 A NO19954135 A NO 19954135A NO 954135 A NO954135 A NO 954135A NO 317547 B1 NO317547 B1 NO 317547B1
- Authority
- NO
- Norway
- Prior art keywords
- virus
- fish
- cells
- fpdv
- disease
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 136
- 208000016222 Pancreatic disease Diseases 0.000 title claims description 42
- 238000000034 method Methods 0.000 title claims description 29
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 24
- 229960005486 vaccine Drugs 0.000 title claims description 19
- 238000002955 isolation Methods 0.000 title claims description 16
- 201000010099 disease Diseases 0.000 title description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 8
- 235000019688 fish Nutrition 0.000 claims description 76
- 241000251468 Actinopterygii Species 0.000 claims description 74
- 238000012360 testing method Methods 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 14
- 241000277263 Salmo Species 0.000 claims description 13
- 238000004448 titration Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 9
- 210000000496 pancreas Anatomy 0.000 claims description 9
- 208000024691 pancreas disease Diseases 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 210000003734 kidney Anatomy 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 241001280377 Oncorhynchus tshawytscha Species 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000013535 sea water Substances 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 97
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 27
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 238000011081 inoculation Methods 0.000 description 21
- 241000972773 Aulopiformes Species 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 235000019515 salmon Nutrition 0.000 description 20
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 230000000120 cytopathologic effect Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 11
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 10
- 101150035271 CHSE gene Proteins 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- 241000277275 Oncorhynchus mykiss Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 239000013505 freshwater Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000295697 Pimephales promelas Species 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 208000010824 fish disease Diseases 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000710803 Equine arteritis virus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000012809 post-inoculation Methods 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000721654 Lepomis macrochirus Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000000578 anorexic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002488 pyknotic effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229940121863 DNA inhibitor Drugs 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000316144 Macrodon ancylodon Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9420956A GB9420956D0 (en) | 1994-10-18 | 1994-10-18 | Virus |
| GBGB9508704.5A GB9508704D0 (en) | 1995-04-28 | 1995-04-28 | Virus |
| GBGB9509425.6A GB9509425D0 (en) | 1995-05-10 | 1995-05-10 | "Virus" |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO954135D0 NO954135D0 (no) | 1995-10-17 |
| NO954135L NO954135L (no) | 1996-04-19 |
| NO317547B1 true NO317547B1 (no) | 2004-11-15 |
Family
ID=27267435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19954135A NO317547B1 (no) | 1994-10-18 | 1995-10-17 | Fiskebukspyttkjertel-sykdomsvirus, fremgangsmate for diagnostisering av sykdom og for isolering av virus, samt vaksine og diagnostisk reagens. |
| NO2011024C NO2011024I2 (no) | 1994-10-18 | 2011-10-28 | Laksepankreassykdomsvirus (SPDV) stamme F93-125;deponert ved ECACC med deponeringsnummer V94090731 eller nært beslektede stammer med lignende genotypiske og/eller fenotypiske karaktertrekk som den deponerte virusstammen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2011024C NO2011024I2 (no) | 1994-10-18 | 2011-10-28 | Laksepankreassykdomsvirus (SPDV) stamme F93-125;deponert ved ECACC med deponeringsnummer V94090731 eller nært beslektede stammer med lignende genotypiske og/eller fenotypiske karaktertrekk som den deponerte virusstammen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5939073A (enExample) |
| EP (1) | EP0712926B1 (enExample) |
| JP (1) | JP3676449B2 (enExample) |
| AT (1) | ATE251667T1 (enExample) |
| CA (1) | CA2160764C (enExample) |
| DE (1) | DE69531891D1 (enExample) |
| DK (1) | DK0712926T3 (enExample) |
| NO (2) | NO317547B1 (enExample) |
| PT (1) | PT712926E (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0626635B1 (en) * | 1993-05-24 | 2003-03-05 | Sun Microsystems, Inc. | Improved graphical user interface with method for interfacing to remote devices |
| JP4323720B2 (ja) | 1998-05-08 | 2009-09-02 | インターベツト・インターナシヨナル・ベー・ベー | 魚膵臓病ウイルス構造タンパク質およびその使用 |
| US20030108901A1 (en) * | 2001-07-17 | 2003-06-12 | Kibenge Frederick S.B. | Serological test for ISAV in fish |
| US6936256B2 (en) * | 2001-08-10 | 2005-08-30 | University Of Maryland Biotechnology Institute | Sub-unit vaccine for infectious pancreatic necrosis virus |
| DE602004028029D1 (en) | 2003-10-07 | 2010-08-19 | Ingrid Dheur | Rwendung |
| DK179025B1 (da) | 2005-09-16 | 2017-08-28 | Intervet Int Bv | Fiskevaccine |
| US8753878B2 (en) | 2006-12-22 | 2014-06-17 | Ewos S.A. | Process and formulation for immunizing fish in aquaculture systems |
| CA2708167C (en) | 2007-12-19 | 2016-11-29 | David Francis Kirke | Vaccine antigens from piscirickettsia salmonis |
| NO333242B1 (no) * | 2008-02-08 | 2013-04-15 | Pharmaq As | Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus |
| NO346489B1 (no) * | 2008-02-08 | 2022-09-05 | Pharmaq As | Anvendelse av inaktivert SAV i fremstilling av en vaksine. |
| WO2012089749A1 (en) | 2010-12-29 | 2012-07-05 | Intervet International B.V. | Salmonid alphavirus protein e2 |
| WO2012130723A1 (en) | 2011-03-25 | 2012-10-04 | Intervet International B.V. | Salmonid alphavirus vaccine |
| EP3037823A1 (en) | 2014-12-22 | 2016-06-29 | BioMar Group A/S | Method for determining pathological tissue damage and diagnosing infectious disease in fish |
| KR102163242B1 (ko) * | 2018-06-05 | 2020-10-08 | 전남대학교산학협력단 | 무지개송어의 면역글로불린 m에 특이적인 단클론항체 및 이의 용도 |
| NO344938B1 (en) | 2018-12-13 | 2020-07-20 | Patogen As | Pancreas Disease Virus Markers |
| CN113122510A (zh) * | 2021-04-12 | 2021-07-16 | 中国水产科学研究院黑龙江水产研究所 | 一种传染性造血器官坏死病疫苗及其病毒在胖头鱥肌肉细胞上扩增的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5165925A (en) * | 1989-05-02 | 1992-11-24 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Vaccine for immunizing fish against infectious pancreatic necrosis virus |
-
1995
- 1995-10-13 DK DK95202771T patent/DK0712926T3/da active
- 1995-10-13 DE DE69531891T patent/DE69531891D1/de not_active Expired - Lifetime
- 1995-10-13 AT AT95202771T patent/ATE251667T1/de active
- 1995-10-13 EP EP95202771A patent/EP0712926B1/en not_active Expired - Lifetime
- 1995-10-13 PT PT95202771T patent/PT712926E/pt unknown
- 1995-10-17 CA CA002160764A patent/CA2160764C/en not_active Expired - Lifetime
- 1995-10-17 NO NO19954135A patent/NO317547B1/no not_active IP Right Cessation
- 1995-10-18 JP JP27017295A patent/JP3676449B2/ja not_active Expired - Lifetime
- 1995-10-18 US US08/544,681 patent/US5939073A/en not_active Expired - Lifetime
-
1997
- 1997-05-08 US US08/854,057 patent/US5914260A/en not_active Expired - Lifetime
-
2011
- 2011-10-28 NO NO2011024C patent/NO2011024I2/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO954135D0 (no) | 1995-10-17 |
| CA2160764C (en) | 2002-09-03 |
| JPH08228770A (ja) | 1996-09-10 |
| NO954135L (no) | 1996-04-19 |
| DE69531891D1 (de) | 2003-11-13 |
| EP0712926A2 (en) | 1996-05-22 |
| DK0712926T3 (da) | 2004-02-09 |
| EP0712926B1 (en) | 2003-10-08 |
| EP0712926A3 (enExample) | 1996-07-03 |
| JP3676449B2 (ja) | 2005-07-27 |
| US5939073A (en) | 1999-08-17 |
| CA2160764A1 (en) | 1996-04-19 |
| NO2011024I1 (no) | 2011-11-14 |
| NO2011024I2 (no) | 2015-09-07 |
| PT712926E (pt) | 2004-02-27 |
| ATE251667T1 (de) | 2003-10-15 |
| US5914260A (en) | 1999-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nelson et al. | Isolation of a toga-like virus from farmed Atlantic salmon Salmo salar with pancreas disease | |
| Kibenge et al. | Isolation and identification of infectious salmon anaemia virus (ISAV) from Coho salmon in Chile | |
| NO317547B1 (no) | Fiskebukspyttkjertel-sykdomsvirus, fremgangsmate for diagnostisering av sykdom og for isolering av virus, samt vaksine og diagnostisk reagens. | |
| Kibenge et al. | Infectious salmon anemia virus: causative agent, pathogenesis and immunity | |
| Tapiovaara et al. | Isolation of an iridovirus from pike-perch Stizostedion lucioperca | |
| Blindheim et al. | A new aquareovirus causing high mortality in farmed Atlantic halibut fry in Norway | |
| Mendelson et al. | Identification and characterization of an avian adenovirus isolated from a ‘spiking mortality syndrome’field outbreak in broilers on the Delmarva Peninsula, USA | |
| Adair et al. | Isolation of infectious pancreatic necrosis (IPN) virus from non‐salmonid fish | |
| US6231868B1 (en) | Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts | |
| McNeilly et al. | Studies on a new enterovirus‐like virus isolated from chickens | |
| Guy et al. | Partial characterization of a turkey enterovirus-like virus | |
| EP3039128B1 (en) | Method for propagating a virus | |
| Seng et al. | Characterisation of a pathogenic virus isolated from marine threadfin fish (Eleutheronema tetradactylus) during a disease outbreak | |
| Hedrick et al. | A small RNA virus isolated from salmonid fishes in California, USA | |
| Winton et al. | Isolation of a new virus from Chinook salmon (Oncorhynchus tshawytscha) in Oregon USA | |
| Koski | A RHABDOVIRUS ISOLATED FROM BROWN TROUT (SALMO TRUTTA m. LACUSTRIS (L.)) WITH LESIONS IN PARENCHYMATOUSn | |
| McAllister et al. | Isolation of infectious pancreatic necrosis virus (serotype Ab) from diverse species of estuarine fish | |
| Zsák et al. | Some biological and physico-chemical properties of egg drop syndrome (EDS) avian adenovirus strain B8/78 | |
| EP0156478A2 (en) | Propagation of group II avian adeno (AA) virus in avian cell culture and vaccine produced | |
| EP1543113B1 (en) | Chicken astrovirus type 2 | |
| Matvienko et al. | Replication of infectious Pancreatic Necrosis Virus in different cell lines and in rainbow trout (Oncorhynchus mykiss) fingerlings | |
| Winton | Isolation and characterization of a new reovirus from chum salmon (Oncorhynchus keta) | |
| Swanson | Studies on the Pathogenesis of Infectious Pancreatic Necrosis and a Description of Three Recent Isolates of Infectious Pancreatic Necrosis Virus from the Northeastern United States | |
| Shaw | The role of non-structural proteins in bluetongue virus replication | |
| Chai | Biological and molecular characterisation and crystallisation of infectious bursal disease virus and its major capsid protein: a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Veterinary Science at Massey University, Turitea, Palmerston North, New Zealand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CB | Opposition filed (par. 26,5 patents act) |
Effective date: 20050812 |
|
| PDP | Decision of opposition (par. 25 patent act) |
Free format text: PATENTSTYRETS 1. AVDELINGS AVGJORELSE AV 20060824, HVORVED TIDLIGERE MEDDELT PATENT BLE BESLUTTET OPPRETTHOLDT MOT INNSIGELSE, ER DEN 20080929 STADFESTET AV 2. AVDELING. AVGJORELSEN ER RETTSKRAFTIG. |
|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: NORVAX COMPACT PD VET.; NAT. REG. NO/DATE: MT NR 10-7431 20110818; FIRST REG. NO/DATE: VM 01708/4551 20110810 Spc suppl protection certif: 2011024 Filing date: 20111028 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: NORVAX COMPACT PD VET. INJEKSJONVAESKE, EMULSJON INTERVET; NAT. REGISTRATION NO/DATE: MT NR 10-7431 20110818; FIRST REGISTRATION: GB VM 01708/4551 20050606 Spc suppl protection certif: 2011024 Filing date: 20111028 Extension date: 20200606 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: NORVAX COMPACT PD VET. INJEKSJONSVÆSKE, EMULSJON "INTERVET"; REG.NO/DATE: MT NR 10-7431 2011.08.18; FIRST REG.NO/DATE: VM 01708/4551 2005.06.06 Spc suppl protection certif: 2011024 Filing date: 20111028 Extension date: 20200606 |
|
| MK1K | Patent expired |